Monitoring Predominantly Cytostatic Treatment Response with 18F-FDG PET

被引：71
作者：
Contractor, Kaiyumars B. [1 ]
Aboagye, Eric O. [1 ]
机构：
[1] Univ London Imperial Coll Sci Technol & Med, Ctr Clin Sci, Dept Oncol, London W12 0NN, England
来源：
JOURNAL OF NUCLEAR MEDICINE | 2009年 / 50卷
基金：
英国医学研究理事会;
关键词：
F-18-FDG PET; cytostatic treatment; cytoreductive therapy; response monitoring; imatinib mesylate; POSITRON-EMISSION-TOMOGRAPHY; GASTROINTESTINAL STROMAL TUMORS; TYROSINE KINASE INHIBITOR; IMATINIB MESYLATE THERAPY; CELL LUNG-CANCER; PHASE-I TRIAL; BREAST-CANCER; FDG-PET; EARLY PREDICTION; COLORECTAL-CANCER;
D O I：
10.2967/jnumed.108.057273
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
F-18-FDG PET and, more recently, PET/CT have been established as response biomarkers for monitoring cytotoxic or cytoreductive cancer therapies. With the advent of targeted cancer therapies, which are predominantly cytostatic, F-18-FDG PET is increasingly being used to monitor the therapeutic response to these agents as well. The impressive outcome of F-18-FDG PET studies in patients with gastrointestinal stromal tumors treated with imatinib mesylate brought to the forefront the use of this biomarker for assessing the response to targeted therapies. The use of F-18-FDG PET for this purpose has practical challenges, including quantitative analysis and timing of scans. This review provides a summary of clinical studies of targeted therapies done to date with F-18-FDG PET and provides guidance on practical issues to ensure the optimal interpretation of imaging data in drug development and for patient care.
引用
收藏
页码：97S / 105S
页数：9
相关论文
共 91 条
[1]   Positron emission tomography imaging of small animals in anticancer drug development [J].
Aboagye, Eric O. .
MOLECULAR IMAGING AND BIOLOGY, 2005, 7 (01) :53-58
[2]  
Agus DB, 1998, CANCER RES, V58, P3009
[3]   Small molecules with EGFR-TK inhibitor activity [J].
Albanell, J ;
Gascón, P .
CURRENT DRUG TARGETS, 2005, 6 (03) :259-274
[4]   Endocrine-responsive breast cancer and strategies for combating resistance [J].
Ali, S ;
Coombes, RC .
NATURE REVIEWS CANCER, 2002, 2 (02) :101-+
[5]   A small animal positron emission tomography study of the effect of chemotherapy and hormonal therapy on the uptake of 2-deoxy-2-[F-18]fluoro-D-glucose in murine models of breast cancer [J].
Aliaga, Antonio ;
Rousseau, Jacques A. ;
Cadorette, Jules ;
Croteau, Etienne ;
van Lier, Johan E. ;
Lecomte, Roger ;
Benard, Francois .
MOLECULAR IMAGING AND BIOLOGY, 2007, 9 (03) :144-150
[6]  
Antoch G, 2004, J NUCL MED, V45, P357
[7]  
Armstrong JG, 2006, NEW ENGL J MED, V354, P2187
[8]   FDG-PET imaging for the evaluation of antiglioma agents in a rat model [J].
Assadian, Sarah ;
Aliaga, Antonio ;
Del Maestro, Rolando F. ;
Evans, Alan C. ;
Bedell, Barry J. .
NEURO-ONCOLOGY, 2008, 10 (03) :292-299
[9]   18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib [J].
Banzo, I. ;
Quirce, R. ;
Martinez-Rodriguez, I. ;
Jimenez-Bonilla, J. F. ;
Sainz-Esteban, A. ;
Barragan, J. ;
Portilla-Quattrociocchi, H. ;
Carril, J. M. .
REVISTA ESPANOLA DE MEDICINA NUCLEAR, 2008, 27 (03) :168-175
[10]   AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].
Batchelor, Tracy T. ;
Sorensen, A. Gregory ;
di Tomaso, Emmanuelle ;
Zhang, Wei-Ting ;
Duda, Dan G. ;
Cohen, Kenneth S. ;
Kozak, Kevin R. ;
Cahill, Daniel P. ;
Chen, Poe-Jou ;
Zhu, Mingwang ;
Ancukiewicz, Marek ;
Mrugala, Maciej M. ;
Plotkin, Scott ;
Drappatz, Jan ;
Louis, David N. ;
Ivy, Percy ;
Scadden, David T. ;
Benner, Thomas ;
Loeffler, Jay S. ;
Wen, Patrick Y. ;
Jain, Rakesh K. .
CANCER CELL, 2007, 11 (01) :83-95
12345678910